Role of exon 2-encoded β-domain of the von Hippel-Lindau tumor suppressor protein

被引:49
作者
Bonicalzi, ME
Groulx, I
de Paulsen, N
Lee, S
机构
[1] Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada
[2] Univ Ottawa, Fac Med, Kidney Res Ctr, Ottawa, ON K1H 8M5, Canada
关键词
D O I
10.1074/jbc.M008295200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Sporadic clear cell renal carcinomas frequently harbor inactivating mutations in exon 2 of the von Hippel-Lindau (VHL) tumor suppressor gene. Here, we examine the effect of the loss of exon 2-encoded beta -domain function on VHL biochemical properties. Exon 2-encoded residues are required for VHL-mediated NEDD8 conjugation on cullin-2 and assembly with hypoxia-inducible factor alpha (HIF alpha) and fibronectin. These residues are not essential for VHL ability to assemble with elongin BC/cullin-2, to display E3 ubiquitin ligase activity in vitro and to confer energy-dependent nuclear import properties to a reporter protein. Localization studies in)HIF-1 alpha -null embryonic cells suggest that exon 2-encoded beta -domain mediates transcription-dependent nuclear/cytoplasmic shuttling of VHL independently of assembly with HIF-1 alpha and oxygen concentration. Exon 2-encoded alpha -helical domain is required for VHL complex formation with BC/cullin-2 and E3 ubiquitin ligase activity, for binding to HIF alpha /fibronectin, but this domain is not essential for transcription-dependent nuclear/cytoplasmic trafficking. VHL-/- renal carcinoma cells expressing beta -domain mutants failed to produce an extracellular fibronectin matrix and to degrade HIF alpha which accumulated exclusively in the nucleus of normorric cells. These results demonstrate that exon 2-encoded residues are involved in two independent functions: substrate protein recognition and transcription-dependent nuclear/cytoplasmic trafficking. They also suggest that beta -domain mutations inactivate VHL function differently than alpha -domain mutations, potentially providing an explanation for the relationship between different mutations of the VHL gene and clinical outcome.
引用
收藏
页码:1407 / 1416
页数:10
相关论文
共 52 条
  • [1] Software and database for the analysis of mutations in the VHL gene
    Béroud, C
    Joly, D
    Gallou, C
    Staroz, F
    Orfanelli, MT
    Junien, C
    [J]. NUCLEIC ACIDS RESEARCH, 1998, 26 (01) : 256 - 258
  • [2] GERMLINE MUTATIONS IN THE VONHIPPEL-LINDAU DISEASE TUMOR-SUPPRESSOR GENE - CORRELATIONS WITH PHENOTYPE
    CHEN, F
    KISHIDA, T
    YAO, M
    HUSTAD, T
    GLAVAC, D
    DEAN, M
    GNARRA, JR
    ORCUTT, ML
    DUH, FM
    GLENN, G
    GREEN, J
    HSIA, YE
    LAMIELL, J
    LI, H
    WEI, MH
    SCHMIDT, L
    TORY, K
    KUZMIN, I
    STACKHOUSE, T
    LATIF, F
    LINEHAN, WM
    LERMAN, M
    ZBAR, B
    [J]. HUMAN MUTATION, 1995, 5 (01) : 66 - 75
  • [3] Production and characterization of human 293 cell lines expressing the site-specific recombinase Cre
    Chen, LN
    Anton, M
    Graham, FL
    [J]. SOMATIC CELL AND MOLECULAR GENETICS, 1996, 22 (06) : 477 - 488
  • [4] Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein
    Cockman, ME
    Masson, N
    Mole, DR
    Jaakkola, P
    Chang, GW
    Clifford, SC
    Maher, ER
    Pugh, CW
    Ratcliffe, PJ
    Maxwell, PH
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (33) : 25733 - 25741
  • [5] Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues
    Corless, CL
    Kibel, AS
    Iliopoulos, O
    Kaelin, WG
    [J]. HUMAN PATHOLOGY, 1997, 28 (04) : 459 - 464
  • [6] INHIBITION OF TRANSCRIPTION ELONGATION BY THE VHL TUMOR-SUPPRESSOR PROTEIN
    DUAN, DR
    PAUSE, A
    BURGESS, WH
    ASO, T
    CHEN, DYT
    GARRETT, KP
    CONAWAY, RC
    CONAWAY, JW
    LINEHAN, WM
    KLAUSNER, RD
    [J]. SCIENCE, 1995, 269 (5229) : 1402 - 1406
  • [7] THE HIV-1 REV ACTIVATION DOMAIN IS A NUCLEAR EXPORT SIGNAL THAT ACCESSES AN EXPORT PATHWAY USED BY SPECIFIC CELLULAR RNAS
    FISCHER, U
    HUBER, J
    BOELENS, WC
    MATTAJ, IW
    LUHRMANN, R
    [J]. CELL, 1995, 82 (03) : 475 - 483
  • [8] SOMATIC MUTATIONS OF THE VON HIPPEL-LINDAU DISEASE TUMOR-SUPPRESSOR GENE IN NONFAMILIAL CLEAR-CELL RENAL-CARCINOMA
    FOSTER, K
    PROWSE, A
    VANDENBERG, A
    FLEMING, S
    HULSBEEK, MMF
    CROSSEY, PA
    RICHARDS, FM
    CAIRNS, P
    AFFARA, NA
    FERGUSONSMITH, MA
    BUYS, CHCM
    MAHER, ER
    [J]. HUMAN MOLECULAR GENETICS, 1994, 3 (12) : 2169 - 2173
  • [9] Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma
    Gnarra, JR
    Duan, DR
    Weng, YK
    Humphrey, JS
    Chen, DYT
    Lee, S
    Pause, A
    Dudley, CF
    Latif, F
    Kuzmin, I
    Schmidt, L
    Duh, FM
    Stackhouse, T
    Chen, F
    Kishida, T
    Wei, MH
    Lerman, MI
    Zbar, B
    Klausner, RD
    Linehan, WM
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1996, 1242 (03): : 201 - 210
  • [10] MUTATIONS OF THE VHL TUMOR-SUPPRESSOR GENE IN RENAL-CARCINOMA
    GNARRA, JR
    TORY, K
    WENG, Y
    SCHMIDT, L
    WEI, MH
    LI, H
    LATIF, F
    LIU, S
    CHEN, F
    DUH, FM
    LUBENSKY, I
    DUAN, DR
    FLORENCE, C
    POZZATTI, R
    WALTHER, MM
    BANDER, NH
    GROSSMAN, HB
    BRAUCH, H
    POMER, S
    BROOKS, JD
    ISAACS, WB
    LERMAN, MI
    ZBAR, B
    LINEHAN, WM
    [J]. NATURE GENETICS, 1994, 7 (01) : 85 - 90